Literature DB >> 8867430

[Contrast media for magnetic resonance tomographic lymph node diagnosis (MR lymphography)].

M Taupitz1, S Wagner, B Hamm.   

Abstract

In MR-imaging, similar to computed tomography, diagnosis of metastatic lymph-node disease is based on lymph-node sizes, and thereby it is non-specific. Super-paramagnetic iron oxide as a potential contrast medium for MR-lymphography accumulate in normal lymph node tissue after endolymphatic, interstitial and, in case of very small particles, after intravenous injection. No accumulation occures in lymph node metastases. Lymph-node metastases can be detected by all three injection techniques. It has been shown experimentally, that in particular small metastases can be detected in normal sized lymph nodes. However, MR-lymphography also has inherent methodologic problems, as there may occure an uneven distribution of the contrast medium between different lymph-node groups. The experimental results with endolymphatic, interstitial, and intravenous MR-lymphography as well as first clinical results with intravenous contrast medium injection are presented and discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8867430     DOI: 10.1007/s001170050050

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  4 in total

1.  Gadofluorine 8: initial experience with a new contrast medium for interstitial MR lymphography.

Authors:  B Misselwitz; J Platzek; B Radüchel; J J Oellinger; H J Weinmann
Journal:  MAGMA       Date:  1999-08       Impact factor: 2.310

2.  [Modern imaging modalities in renal disease: CT and MRI].

Authors:  P Rogalla; M Taupitz; B Hamm
Journal:  Urologe A       Date:  2003-02-01       Impact factor: 0.639

Review 3.  Contrast-enhanced MR imaging of lymph nodes in cancer patients.

Authors:  Seung Hong Choi; Woo Kyung Moon
Journal:  Korean J Radiol       Date:  2010-06-21       Impact factor: 3.500

Review 4.  Structural and functional photoacoustic molecular tomography aided by emerging contrast agents.

Authors:  Liming Nie; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2014       Impact factor: 54.564

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.